Cargando…

Characteristics and long‐term outcomes of advanced pleural mesothelioma in Latin America (MeSO‐CLICaP)

BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive tumor, associated with poor prognosis. There is a lack of information about the clinical and pathological features related with survival in the Latin American population. METHODS: The MeSO‐CLICaP registry identified 302 patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Rojas, Leonardo, Cardona, Andrés F., Trejo‐Rosales, Rogelio, Zatarain‐Barrón, Zyanya Lucia, Ramírez‐Tirado, Laura‐Alejandra, Ruiz‐Patiño, Alejandro, Campos Gómez, Saúl, Corrales, Luis, Oblitas, George, Bacon, Ludwing, Martín, Claudio, de Lima, Vladmir C. Cordeiro, Freitas, Helano C., Mas, Luis, Vargas, Carlos, Carranza, Hernán, Otero, Jorge, Pérez, María Angelina, González, Lisde, Chirinos, Luis, Granados, Sara T., Rodriguez, July, Báez, Renata, Remolina Bonilla, Yuly‐Andrea, Núñez Cerrillo, Gustavo, Archila, Pilar, Cuello, Mauricio, Karachaliou, Niki, Rosell, Rafael, Arrieta, Oscar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397921/
https://www.ncbi.nlm.nih.gov/pubmed/30706690
http://dx.doi.org/10.1111/1759-7714.12967
_version_ 1783399488918913024
author Rojas, Leonardo
Cardona, Andrés F.
Trejo‐Rosales, Rogelio
Zatarain‐Barrón, Zyanya Lucia
Ramírez‐Tirado, Laura‐Alejandra
Ruiz‐Patiño, Alejandro
Campos Gómez, Saúl
Corrales, Luis
Oblitas, George
Bacon, Ludwing
Martín, Claudio
de Lima, Vladmir C. Cordeiro
Freitas, Helano C.
Mas, Luis
Vargas, Carlos
Carranza, Hernán
Otero, Jorge
Pérez, María Angelina
González, Lisde
Chirinos, Luis
Granados, Sara T.
Rodriguez, July
Báez, Renata
Remolina Bonilla, Yuly‐Andrea
Núñez Cerrillo, Gustavo
Archila, Pilar
Cuello, Mauricio
Karachaliou, Niki
Rosell, Rafael
Arrieta, Oscar
author_facet Rojas, Leonardo
Cardona, Andrés F.
Trejo‐Rosales, Rogelio
Zatarain‐Barrón, Zyanya Lucia
Ramírez‐Tirado, Laura‐Alejandra
Ruiz‐Patiño, Alejandro
Campos Gómez, Saúl
Corrales, Luis
Oblitas, George
Bacon, Ludwing
Martín, Claudio
de Lima, Vladmir C. Cordeiro
Freitas, Helano C.
Mas, Luis
Vargas, Carlos
Carranza, Hernán
Otero, Jorge
Pérez, María Angelina
González, Lisde
Chirinos, Luis
Granados, Sara T.
Rodriguez, July
Báez, Renata
Remolina Bonilla, Yuly‐Andrea
Núñez Cerrillo, Gustavo
Archila, Pilar
Cuello, Mauricio
Karachaliou, Niki
Rosell, Rafael
Arrieta, Oscar
author_sort Rojas, Leonardo
collection PubMed
description BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive tumor, associated with poor prognosis. There is a lack of information about the clinical and pathological features related with survival in the Latin American population. METHODS: The MeSO‐CLICaP registry identified 302 patients with advanced MPM diagnosed and treated between January 2008 and March 2016. The Cox model was applied to determine the variables associated with survival. A random forest tree model was built to predict the response to first‐line chemotherapy among Latin American patients. RESULTS: The median age was 61.1 years (SD 10.6 years), 191 (63.2%) were men, 65.9% were ever smokers, and 38.7% had previous exposure to asbestos. A total of 237 (78.5%) had epithelioid tumors, and 188 (62.3%) and 114 (37.7%) cases had stage III or IV MPM, respectively. A total of 49 patients (16.2%) underwent pleurectomy, 57 (18.9%) received radiotherapy, and 279 patients received first‐line platinum‐based chemotherapy. The overall response rate to first‐line chemotherapy was 40.4%, progression‐free survival to first‐line treatment was 5.7 months (95% CI 4.9–6.5), and 63 (20.8%) patients had pemetrexed maintenance. The median overall survival was 16.8 months (95% CI 13.0–20.5), and multivariate analysis found that stage (P = 0.013), and pleurodesis (P = 0.048), were independent prognostic factors for first‐line overall survival. The model to predict response to first‐line chemotherapy obtained a 0.98 area under the curve, a sensitivity of 93%, and a specificity of 95% for detecting responders and non‐responders. CONCLUSION: This study identifies factors associated with clinical benefit from chemotherapy among advanced MPM Latin American patients, emphasizing the impact of histology and the clinical benefit of chemotherapy on outcomes.
format Online
Article
Text
id pubmed-6397921
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-63979212019-03-04 Characteristics and long‐term outcomes of advanced pleural mesothelioma in Latin America (MeSO‐CLICaP) Rojas, Leonardo Cardona, Andrés F. Trejo‐Rosales, Rogelio Zatarain‐Barrón, Zyanya Lucia Ramírez‐Tirado, Laura‐Alejandra Ruiz‐Patiño, Alejandro Campos Gómez, Saúl Corrales, Luis Oblitas, George Bacon, Ludwing Martín, Claudio de Lima, Vladmir C. Cordeiro Freitas, Helano C. Mas, Luis Vargas, Carlos Carranza, Hernán Otero, Jorge Pérez, María Angelina González, Lisde Chirinos, Luis Granados, Sara T. Rodriguez, July Báez, Renata Remolina Bonilla, Yuly‐Andrea Núñez Cerrillo, Gustavo Archila, Pilar Cuello, Mauricio Karachaliou, Niki Rosell, Rafael Arrieta, Oscar Thorac Cancer Original Articles BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive tumor, associated with poor prognosis. There is a lack of information about the clinical and pathological features related with survival in the Latin American population. METHODS: The MeSO‐CLICaP registry identified 302 patients with advanced MPM diagnosed and treated between January 2008 and March 2016. The Cox model was applied to determine the variables associated with survival. A random forest tree model was built to predict the response to first‐line chemotherapy among Latin American patients. RESULTS: The median age was 61.1 years (SD 10.6 years), 191 (63.2%) were men, 65.9% were ever smokers, and 38.7% had previous exposure to asbestos. A total of 237 (78.5%) had epithelioid tumors, and 188 (62.3%) and 114 (37.7%) cases had stage III or IV MPM, respectively. A total of 49 patients (16.2%) underwent pleurectomy, 57 (18.9%) received radiotherapy, and 279 patients received first‐line platinum‐based chemotherapy. The overall response rate to first‐line chemotherapy was 40.4%, progression‐free survival to first‐line treatment was 5.7 months (95% CI 4.9–6.5), and 63 (20.8%) patients had pemetrexed maintenance. The median overall survival was 16.8 months (95% CI 13.0–20.5), and multivariate analysis found that stage (P = 0.013), and pleurodesis (P = 0.048), were independent prognostic factors for first‐line overall survival. The model to predict response to first‐line chemotherapy obtained a 0.98 area under the curve, a sensitivity of 93%, and a specificity of 95% for detecting responders and non‐responders. CONCLUSION: This study identifies factors associated with clinical benefit from chemotherapy among advanced MPM Latin American patients, emphasizing the impact of histology and the clinical benefit of chemotherapy on outcomes. John Wiley & Sons Australia, Ltd 2019-01-31 2019-03 /pmc/articles/PMC6397921/ /pubmed/30706690 http://dx.doi.org/10.1111/1759-7714.12967 Text en © 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Rojas, Leonardo
Cardona, Andrés F.
Trejo‐Rosales, Rogelio
Zatarain‐Barrón, Zyanya Lucia
Ramírez‐Tirado, Laura‐Alejandra
Ruiz‐Patiño, Alejandro
Campos Gómez, Saúl
Corrales, Luis
Oblitas, George
Bacon, Ludwing
Martín, Claudio
de Lima, Vladmir C. Cordeiro
Freitas, Helano C.
Mas, Luis
Vargas, Carlos
Carranza, Hernán
Otero, Jorge
Pérez, María Angelina
González, Lisde
Chirinos, Luis
Granados, Sara T.
Rodriguez, July
Báez, Renata
Remolina Bonilla, Yuly‐Andrea
Núñez Cerrillo, Gustavo
Archila, Pilar
Cuello, Mauricio
Karachaliou, Niki
Rosell, Rafael
Arrieta, Oscar
Characteristics and long‐term outcomes of advanced pleural mesothelioma in Latin America (MeSO‐CLICaP)
title Characteristics and long‐term outcomes of advanced pleural mesothelioma in Latin America (MeSO‐CLICaP)
title_full Characteristics and long‐term outcomes of advanced pleural mesothelioma in Latin America (MeSO‐CLICaP)
title_fullStr Characteristics and long‐term outcomes of advanced pleural mesothelioma in Latin America (MeSO‐CLICaP)
title_full_unstemmed Characteristics and long‐term outcomes of advanced pleural mesothelioma in Latin America (MeSO‐CLICaP)
title_short Characteristics and long‐term outcomes of advanced pleural mesothelioma in Latin America (MeSO‐CLICaP)
title_sort characteristics and long‐term outcomes of advanced pleural mesothelioma in latin america (meso‐clicap)
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397921/
https://www.ncbi.nlm.nih.gov/pubmed/30706690
http://dx.doi.org/10.1111/1759-7714.12967
work_keys_str_mv AT rojasleonardo characteristicsandlongtermoutcomesofadvancedpleuralmesotheliomainlatinamericamesoclicap
AT cardonaandresf characteristicsandlongtermoutcomesofadvancedpleuralmesotheliomainlatinamericamesoclicap
AT trejorosalesrogelio characteristicsandlongtermoutcomesofadvancedpleuralmesotheliomainlatinamericamesoclicap
AT zatarainbarronzyanyalucia characteristicsandlongtermoutcomesofadvancedpleuralmesotheliomainlatinamericamesoclicap
AT ramireztiradolauraalejandra characteristicsandlongtermoutcomesofadvancedpleuralmesotheliomainlatinamericamesoclicap
AT ruizpatinoalejandro characteristicsandlongtermoutcomesofadvancedpleuralmesotheliomainlatinamericamesoclicap
AT camposgomezsaul characteristicsandlongtermoutcomesofadvancedpleuralmesotheliomainlatinamericamesoclicap
AT corralesluis characteristicsandlongtermoutcomesofadvancedpleuralmesotheliomainlatinamericamesoclicap
AT oblitasgeorge characteristicsandlongtermoutcomesofadvancedpleuralmesotheliomainlatinamericamesoclicap
AT baconludwing characteristicsandlongtermoutcomesofadvancedpleuralmesotheliomainlatinamericamesoclicap
AT martinclaudio characteristicsandlongtermoutcomesofadvancedpleuralmesotheliomainlatinamericamesoclicap
AT delimavladmirccordeiro characteristicsandlongtermoutcomesofadvancedpleuralmesotheliomainlatinamericamesoclicap
AT freitashelanoc characteristicsandlongtermoutcomesofadvancedpleuralmesotheliomainlatinamericamesoclicap
AT masluis characteristicsandlongtermoutcomesofadvancedpleuralmesotheliomainlatinamericamesoclicap
AT vargascarlos characteristicsandlongtermoutcomesofadvancedpleuralmesotheliomainlatinamericamesoclicap
AT carranzahernan characteristicsandlongtermoutcomesofadvancedpleuralmesotheliomainlatinamericamesoclicap
AT oterojorge characteristicsandlongtermoutcomesofadvancedpleuralmesotheliomainlatinamericamesoclicap
AT perezmariaangelina characteristicsandlongtermoutcomesofadvancedpleuralmesotheliomainlatinamericamesoclicap
AT gonzalezlisde characteristicsandlongtermoutcomesofadvancedpleuralmesotheliomainlatinamericamesoclicap
AT chirinosluis characteristicsandlongtermoutcomesofadvancedpleuralmesotheliomainlatinamericamesoclicap
AT granadossarat characteristicsandlongtermoutcomesofadvancedpleuralmesotheliomainlatinamericamesoclicap
AT rodriguezjuly characteristicsandlongtermoutcomesofadvancedpleuralmesotheliomainlatinamericamesoclicap
AT baezrenata characteristicsandlongtermoutcomesofadvancedpleuralmesotheliomainlatinamericamesoclicap
AT remolinabonillayulyandrea characteristicsandlongtermoutcomesofadvancedpleuralmesotheliomainlatinamericamesoclicap
AT nunezcerrillogustavo characteristicsandlongtermoutcomesofadvancedpleuralmesotheliomainlatinamericamesoclicap
AT archilapilar characteristicsandlongtermoutcomesofadvancedpleuralmesotheliomainlatinamericamesoclicap
AT cuellomauricio characteristicsandlongtermoutcomesofadvancedpleuralmesotheliomainlatinamericamesoclicap
AT karachaliouniki characteristicsandlongtermoutcomesofadvancedpleuralmesotheliomainlatinamericamesoclicap
AT rosellrafael characteristicsandlongtermoutcomesofadvancedpleuralmesotheliomainlatinamericamesoclicap
AT arrietaoscar characteristicsandlongtermoutcomesofadvancedpleuralmesotheliomainlatinamericamesoclicap
AT characteristicsandlongtermoutcomesofadvancedpleuralmesotheliomainlatinamericamesoclicap